The US FDA has approved Skinvive by Juvéderm for the treatment of neck lines and improvement of neck appearance, extending the hyaluronic acid franchise beyond the face.

The approval marks a new indication for the Juvéderm family, whose products are manufactured and marketed by Allergan Aesthetics, an AbbVie company. Skinvive had previously been positioned in the US market as a hyaluronic acid intradermal injection, and the neck indication broadens its labeled use into a zone where injectable options have historically been limited.

What does the approval change?

Neck lines have long sat in a treatment gap. Botulinum toxins, resurfacing lasers and energy-based devices each address part of the problem, but a labeled injectable indication for neck lines and neck appearance gives aesthetic clinicians a regulatory-cleared option in the same category they already use for midface and perioral correction.

For practices, the approval matters on three fronts:

• It adds a labeled neck indication to a well-established hyaluronic acid brand, which can streamline consent and marketing conversations.
• It gives clinic staff a familiar injection platform for a treatment area that has lacked a dedicated FDA-cleared injectable.
• It positions Allergan Aesthetics to compete in the neck segment, where consumer demand has grown alongside face-and-neck combination treatment planning.

How does this fit the Juvéderm portfolio?

Juvéderm remains one of the most widely used hyaluronic acid filler lines in the US aesthetic market. The Skinvive entry differentiates itself from traditional volume fillers: rather than acting primarily as a space-occupying gel, the product is designed around skin-quality improvement, an approach the brand has marketed as delivering hydrated, smoother-looking skin.

The new neck labeling now pairs that skin-quality mechanism with a structural complaint — horizontal neck lines — in a single indication covering both line correction and overall appearance.

As with all aesthetic approvals, manufacturers' claims about clinical performance sit alongside, not in place of, the trial data submitted to FDA. Specifics on study design, injection volumes, durability and adverse-event rates for the neck indication were not included in the announcement, and clinicians will want the full prescribing information before mapping treatment protocols.

What comes next?

Expect the approval to accelerate activity in the neck-aesthetics segment, where device makers and injectable developers have been racing to establish claims. Further detail on dosing, longevity and patient-selection criteria for the neck indication should emerge as Allergan Aesthetics rolls out training and labeling materials in coming months.